Holen Sie sich die Stockscreener-App
3.43
0.88%
0.03
Handel nachbörslich:
3.43
Schlusskurs vom Vortag:
$3.40
Offen:
$3.45
24-Stunden-Volumen:
1,175
Relative Volume:
0.06
Marktkapitalisierung:
$11.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.16%
1M Leistung:
+1.78%
6M Leistung:
+23.83%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.41
$3.46
1-Wochen-Bereich:
$3.25
$3.47
52-Wochen-Spanne:
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
Firmenname
Cosciens Biopharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CSCI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
3.43 | 11.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cosciens Biopharma Inc Aktie (CSCI) Neueste Nachrichten
TSX:CSCI Forum Post | prophetoffactz-36604398 | PGX-YBG | COSCIENS Biopharma Inc - Stockhouse
COSCIENS Biopharma reports on forward-looking statements By Investing.com - Investing.com South Africa
COSCIENS Biopharma Announces Virtual Shareholder Meeting on June 30, 2025 - TipRanks
COSCIENS Biopharma reports on forward-looking statements - Investing.com
AEZSAeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders - mx.advfn.com
COSCIENS Biopharma reconstitutes board - MSN
COSCIENS BiopharmaEnters Resolution Agreement With Goodwood, Goodwood Fund, And Puccetti Funds Management - marketscreener.com
COSCIENS Biopharma Schedules Virtual Annual Meeting for June 30, 2025 - TipRanks
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Share - GuruFocus
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | CSCI Stock News - GuruFocus
Cosciens Biopharma Brief: Entering Into a Resolution Agreement With Goodwood Inc. As Co Reconstitutes Board for Benefit of Shareholders - marketscreener.com
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders - The Manila Times
COSCIENS Biopharma Overhauls Board with Pharma Veterans After 8.2% Stakeholder Agreement - Stock Titan
Cosciens Biopharma announces receipt of Goodwood intended director nominations - Yahoo Finance
COSCIENS Biopharma Receives Director Nominations Ahead of Shareholder Meeting - TipRanks
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Directo - GuruFocus
COSCIENS Biopharma Receives Director Nominations from Goodwood - TipRanks
COSCIENS Biopharma Inc. Acknowledges Director Nominations from Goodwood Fund Ahead of Annual Shareholder Meeting - Nasdaq
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - The Manila Times
Cosciens Biopharma Brief: Acknowledging Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - marketscreener.com
Activist Investor Goodwood Nominates 6 Directors to COSCIENS Board | CSCI Stock News - Stock Titan
Goodwood Seeks Board Overhaul At Cosciens Biopharma - Finimize
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc. - The Globe and Mail
Goodwood To Nominate New Directors For COSCIENS Biopharma Inc. - Barchart.com
Databricks Announces 2025 Data + AI Summit Keynote Lineup and Data Intelligence Programming - The Globe and Mail
COSCIENS Biopharma Reports Q1 2025 Results and Updates - TipRanks
COSCIENS Biopharma reports key corporate updates By Investing.com - Investing.com India
COSCIENS Biopharma reports key corporate updates - Investing.com
COSCIENS Biopharma Completes Merger with Ceapro and Restructures Governance - TipRanks
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE) - The Globe and Mail
COSCIENS Biopharma: Q1 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q1 2025 results, updates strategy By Investing.com - Investing.com Nigeria
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Res - GuruFocus
COSCIENS Biopharma reports Q1 2025 results, updates strategy - Investing.com
COSCIENS Biopharma Reports Q1 2025 Results and Strategic Updates - TipRanks
COSCIENS Biopharma Reports Q1 2025 Financial Results Amid Strategic Shifts - TipRanks
Cosciens Biopharma Brief: Appointing Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - marketscreener.com
Cosciens Biopharma Brief: Company Says Ended Quarter with US$13.8 Million in Cash - marketscreener.com
Cosciens Biopharma Brief: Reported a Q1 Consolidated Net Loss of US$3.7 Million, or $1.16 Loss Per Common Share - marketscreener.com
COSCIENS Biopharma Inc. Transitions to Pure-Play Natural Products Company, Announces Phase 2 Clinical Trial Advancements and New CEO Appointment - Nasdaq
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Yahoo Finance
COSCIENS Earnings Reveal Strategic Pivot to Natural Products While Advancing Key Clinical Trial - Stock Titan
COSCIENS Biopharma Inc. Reports Transformative Year - TipRanks
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
Finanzdaten der Cosciens Biopharma Inc-Aktie (CSCI)
Es liegen keine Finanzdaten für Cosciens Biopharma Inc (CSCI) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):